We use cookies for a better user experience. Read our Privacy Policy

I Agree

HER2 Breast Cancer Test Market Trends, 2021-2031

HER2 Breast Cancer Test Market (Test Type: Immunohistochemistry [IHC] and Fluorescence/Chromogenic In Situ Hybridization [FISH/CISH]; and End-user: Hospitals and Diagnostic Laboratories) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Telehealth Helps Avoid Delay in Breast Cancer Treatment amid Coronavirus Outbreak

The coronavirus outbreak has affected screening, diagnosis, treatment, and follow-up care for breast cancer. This is why the HER2 breast cancer test market is expanding in a staggered manner during the ongoing pandemic. Many individuals are fearing the contraction of the novel infection, leading to postponement and cancellation of treatments and screening. Nevertheless, telehealth services and mobile apps hold promising potentials to avoid delay in treatment of potential patients.

Since many countries have lifted their stay-at-home orders and allowed businesses to re-open, revenue flow is anticipated to grow in the HER2 breast cancer test market. Healthcare providers are extending their arms to provide essential and critical services to improve the patient quality of life during the ongoing pandemic.

Request a sample to get extensive insights into the HER2 Breast Cancer Test Market

Inaccurate HER2 Test Results with IHC Affect Market Growth

The HER2 breast cancer test market is expected to reach US$ 627.7 Mn by 2031. Immunohistochemistry (IHC) is being publicized as the gold standard for HER2 breast cancer testing. However, it has been found that some HER2 test results may be inaccurate, as different labs have different rules for classifying positive and negative HER2 status. Such findings are anticipated to affect market growth.

Inaccurate HER2 test results may deprive women diagnosed with breast cancer of proper care and treatment. Hence, healthcare providers in the HER2 breast cancer test market are increasing awareness about multiple reviewing of HER2 test results from more than one pathologist to attain certainty in outcomes.

To understand how our report can bring difference to your business strategy, Ask for a brochure

FISH Test V/S IHC Test: Which is Better?

The FISH (Fluorescence In Situ Hybridization) test is not as widely available as compared to IHC. However, it has been found that FISH test in more accurate and reliable than IHC. In many cases, a lab will do the IHC test first and order FISH test only if the IHC results do not clearly show whether the cells are HER2-positive or negative.

The HER2 breast cancer test market is expected to register a CAGR of 6.5% during the forecast period. The growing popularity of FISH test helps to map the genetic material in a person’s cells. This test is used to visualize specific genes or portions of genes.

HER2 Testing Becoming Routine Practice for Newly Diagnosed Breast Cancer

IHC and FISH tests are gaining popularity for proper diagnosis, treatment, and follow-up care for HER2 breast cancer. HER2 testing is becoming a routine practice for newly diagnosed breast cancer in pathology. Bright-field in situ hybridization such as chromogenic in situ hybridization (CISH) has an advantage, since it allows histologic evaluation of tumors, utilizes ordinary microscope, can be fully automated, and leaves permanent signals for archival storage.

The CISH test is emerging as a suitable alternative to FISH test. Such trends are contributing to the growth of the HER2 breast cancer test market. For uniformity in accuracy and reproducibility of HER2 testing in breast cancer, the ASCO (American Society of Clinical Oncology) has released guidelines for the interpretation of HER2 status.

Stuck in a neck-to-neck competition with other brands? Request a custom report on HER2 Breast Cancer Test Market

Analysts’ Viewpoint

Virtual medical appointments hold potentials in increasing healthcare utilization post the COVID-19 period. Since HER2 testing is associated with inaccuracy in results, healthcare providers, and labs in the HER2 breast cancer test market should adhere to the guidelines issued by the CAP (College of American Pathologists) to address a wide range of pre-analytic, analytic, and post-analytic variables. Apart from testing, companies in the HER2 breast cancer test market should unlock growth opportunities in increasing the availability of treatments such as enhertu, Herceptin, and kadcyla to improve patient outcomes. IHC test and FISH test remain the gold standard for efficient diagnosis of HER2 breast cancer.

HER2 Breast Cancer Test Market: Overview

  • HER2 stands for human epidermal growth factor receptor 2. It is involved in normal cell growth. Women newly detected with invasive breast cancer should be tested for HER2. The application of HER2 testing is to define whether cancer cells have too many copies of the HER2 gene or cancer cells are in developed stage. Cancers with higher-than-normal levels of HER2 are called HER2-positive. Cancers with normal HER2 levels are called HER2-negative.
  • HER2 status is primarily determined using immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH). IHC assesses the expression of the HER2 protein in cell membranes and FISH assesses HER2 gene amplification.
  • Immunohistochemistry (IHC) is the common application of immunostaining. It includes the process of selectively isolating antigens (proteins) in cells of a tissue section by using the principle of antibodies binding specifically to antigens in biological tissues. Fluorescence in situ hybridization (FISH) is a laboratory technique to identify and locate a specific DNA sequence on a chromosome.

HER2 Breast Cancer Test Market: Key Drivers

  • Rise in prevalence of breast cancer across the globe is projected to drive the global HER2 breast cancer test market during the forecast period. Breast cancer in women is a primary health burden globally. According to the World Health Organization (WHO), 2.3 million women were diagnosed with breast cancer in 2020, with 685,000 deaths globally. As of end of 2020, there were 7.8 million women alive who were diagnosed with breast cancer in the past five years, making it the world’s most prevalent cancer. Significant disability-adjusted life years (DALYs) are lost by women to breast cancer globally than any other type of cancer.
  • Breast cancer management can be highly effective, particularly when the disease is identified early. Key players in the cancer treatment market are increasing research and development activities for early detection and cure of cancer. This factor is anticipated to drive the global HER2 breast cancer test market during the forecast period.
  • Treatment of breast cancer often comprises surgical removal, radiation therapy, and medication (hormonal therapy, chemotherapy, and/or targeted biological therapy) to treat microscopic cancer that has spread from the breast tumor through the blood. The treatment inhibits cancer growth and spread.

Market Segmentation: HER2 Breast Cancer Test Market

  • In terms of type, the global HER2 breast cancer test market has been classified into immunohistochemistry (IHC) and fluorescence/chromogenic in situ hybridization (FISH/CISH)
  • Based on end-user, the global HER2 breast cancer test market has been divided into hospitals and diagnostic laboratories
  • Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights. The HER2 breast cancer test market report provides current and expected revenue (US$ Mn) for each of these segments from 2021 to 2031, considering 2020 as the base year. The compound annual growth rate (percentage CAGR) has been provided for each segment and market from 2021 to 2031 along with market size estimations.

Regional Overview: HER2 Breast Cancer Test Market

  • In terms of region, the global HER2 breast cancer test market has been segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa
  • The HER2 breast cancer test market in Europe was valued at US$ 106.1 Mn in 2020 and is projected to reach US$ 207.2 Mn by 2031, expanding at a CAGR of 6.3% from 2021 to 2031
  • The HER2 breast cancer test market in Europe is driven by increase in incidence of breast cancer. According to the European Cancer Information System (ECIS), in 2018, breast cancer was the most common cancer among women, with incidence of 29.2% of all cancers in the European Union (EU-28).

Major Players

  • The HER2 breast cancer test market report concludes with the company profiles section, which includes key information about major players in the global HER2 breast cancer test market
  • Leading players analyzed in the report include
    • Abbott Molecular, Inc.
    • Biogenex Laboratories, Inc.
    • Leica Biosystems
    • Roche
    • Agilent Technologies
    • Mylab Discovery Solutions Pvt. Ltd.
  • Each of these players has been profiled in the HER2 breast cancer test market report based on parameters such as company overview, financial overview, business strategies, application portfolio, business segments, and recent developments

HER2 Breast Cancer Test Market Snapshot

Attribute

Detail

Market Size Value in 2020

US$ 313.4 Mn

Market Forecast Value in 2031

US$ 627.7 Mn

Growth Rate (CAGR)

6.5%

Forecast Period

2021–2031

Historical Data Available for

2017–2019

Quantitative Units

US$ Mn for Value

Market Analysis

It includes cross segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market share analysis by company (2020)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Test Type
    • Immunohistochemistry (IHC)
    • Fluorescence/chromogenic in situ hybridization (FISH/CISH)
  • End-user
    • Hospitals
    • Diagnostic Laboratories

Regions Covered

  • North America
  • Latin America
  • Europe
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Abbott Molecular, Inc.
  • Biogenex Laboratories, Inc.
  • Leica Biosystems
  • Roche
  • Agilent Technologies
  • Mylab Discovery Solutions Pvt. Ltd.

Customization Scope

Available upon request

Pricing

Available upon request

HER2 Breast Cancer Test Market - Segmentation

TMR’s study on the global HER2 breast cancer test market includes information divided into six segments: test type, end-user, and region. Changing industry trends and other market dynamics associated with these segments of the global HER2 breast cancer test market are discussed in detail.

Test Type
  • Immunohistochemistry (IHC)
  • Fluorescence/Chromogenic In Situ Hybridization (FISH/CISH)
End-user
  • Hospitals
  • Diagnostic Laboratories
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
HER2 Breast Cancer Test Market Trends, 2021-2031

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of HER2 breast cancer test market?

HER2 breast cancer test market is expected to reach US$ 627.7 Mn by 2031

What is the anticipated CAGR of the HER2 breast cancer test market in the forecast period?

HER2 breast cancer test market is expected to register a CAGR of 6.5% during 2021-2031

What are the key driving factors for the growth of the HER2 breast cancer test market?

HER2 breast cancer test market is driven by rise in prevalence of breast cancer across the globe

What are the end-use segments in the HER2 breast cancer test market?

The end-use segments in HER2 breast cancer test market are hospitals and diagnostic laboratories.

Who are the key players in the global HER2 breast cancer test market?

Key players operating in the global market include Abbott Molecular Inc., Biogenex Laboratories, Inc., Leica Biosystems, Roche, Agilent Technologies

1. Preface

    1.1. Report Scope and Market Segmentation

    1.2. Research Highlights

2. Assumptions and Research Methodology

    2.1. Assumptions and Acronyms Used

    2.2. Research Methodology

3. Executive Summary

4. Market Overview

    4.1. Introduction

    4.2. Global HER2 Breast Cancer Test Market Forecast

    4.3. Global HER2 Breast Cancer Test Market Outlook

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunity

5. Key Insights

    5.1. Revenue Model

    5.2. Pricing Analysis

    5.3. COVID-19 Impact Analysis

6. Global HER2 Breast Cancer Test Market Analysis, by Test Type

    6.1. Introduction

    6.2. Global HER2 Breast Cancer Test Market Value Share Analysis, by Test Type

    6.3. Global HER2 Breast Cancer Test Market Forecast, by Test Type

        6.3.1. Immunohistochemistry (IHC)

        6.3.2. Fluorescence/Chromogenic In Situ Hybridization (FISH/CISH)

    6.4. Global HER2 Breast Cancer Test Market Analysis, by Test Type

    6.5. Global HER2 Breast Cancer Test Market Attractiveness Analysis, by Test Type

7. Global HER2 Breast Cancer Test Market Analysis, by End-user

    7.1. Introduction

    7.2. Global HER2 Breast Cancer Test Market Value Share Analysis, by End-user

    7.3. Global HER2 Breast Cancer Test Market Forecast, by End-user

        7.3.1. Hospitals

        7.3.2. Diagnostic Laboratories

    7.4. Global HER2 Breast Cancer Test Market Analysis, by End-user

    7.5. Global HER2 Breast Cancer Test Market Attractiveness Analysis, by End-user

8. Global HER2 Breast Cancer Test Market Analysis, by Region

    8.1. Introduction

    8.2. Global HER2 Breast Cancer Test Market Value Share Analysis, by Region

    8.3. Global HER2 Breast Cancer Test Market Forecast, by Region

        8.3.1. North America

        8.3.2. Europe

        8.3.3. Asia Pacific

        8.3.4. Latin America

        8.3.5. Middle East & Africa

9. North America HER2 Breast Cancer Test Market Analysis

    9.1. North America HER2 Breast Cancer Test Market Overview

    9.2. North America HER2 Breast Cancer Test Market Value Share and Attractiveness Analysis, by Country

        9.2.1. U.S.

        9.2.2. Canada

    9.3. North America HER2 Breast Cancer Test Market Value Share and Attractiveness analysis, by Test Type

    9.4. North America HER2 Breast Cancer Test Market Forecast, by Test Type

        9.4.1. Immunohistochemistry (IHC)

        9.4.2. Fluorescence/Chromogenic In Situ Hybridization (FISH/CISH)

    9.5. North America HER2 Breast Cancer Test Market Value Share and Attractiveness Analysis, by End-user

    9.6. North America HER2 Breast Cancer Test Market Forecast, by End-user

        9.6.1. Hospitals

        9.6.2. Diagnostic Laboratories

10. Europe HER2 Breast Cancer Test Market Analysis

    10.1. Europe HER2 Breast Cancer Test Market Overview

    10.2. Europe HER2 Breast Cancer Test Market Value Share and Attractiveness analysis, by Country/Sub-region

        10.2.1. Germany

        10.2.2. U.K.

        10.2.3. France

        10.2.4. Italy

        10.2.5. Spain

        10.2.6. Rest of Europe

    10.3. Europe HER2 Breast Cancer Test Market Value Share and Attractiveness Analysis, by Test Type

    10.4. Europe HER2 Breast Cancer Test Market Forecast, by Test Type

        10.4.1. Immunohistochemistry (IHC)

        10.4.2. Fluorescence/Chromogenic In Situ Hybridization (FISH/CISH)

    10.5. Europe HER2 Breast Cancer Test Market Value Share and Attractiveness Analysis, by End-user

    10.6. Europe HER2 Breast Cancer Test Market Forecast, by End-user

        10.6.1. Hospitals

        10.6.2. Diagnostic Laboratories

11. Asia Pacific HER2 Breast Cancer Test Market Analysis

    11.1. Asia Pacific HER2 Breast Cancer Test Market Overview

    11.2. Asia Pacific HER2 Breast Cancer Test Market Value Share and Attractiveness Analysis, by Country/Sub-region

        11.2.1. China

        11.2.2. Japan

        11.2.3. India

        11.2.4. Australia & New Zealand

        11.2.5. Rest of Asia Pacific

    11.3. Asia Pacific HER2 Breast Cancer Test Market Value Share and Attractiveness analysis, by Test Type

    11.4. Asia Pacific HER2 Breast Cancer Test Market Forecast, by Test Type

        11.4.1. Immunohistochemistry (IHC)

        11.4.2. Fluorescence/Chromogenic In Situ Hybridization (FISH/CISH)

    11.5. Asia Pacific HER2 Breast Cancer Test Market Value Share and Attractiveness analysis, by End-user

    11.6. Asia Pacific HER2 Breast Cancer Test Market Forecast, by End-user

        11.6.1. Hospitals

        11.6.2. Diagnostic Laboratories

12. Latin America HER2 Breast Cancer Test Market Analysis

    12.1. Latin America HER2 Breast Cancer Test Market Overview

    12.2. Latin America HER2 Breast Cancer Test Market Value Share and Attractiveness analysis, by Country/Sub-region

        12.2.1. Brazil

        12.2.2. Mexico

        12.2.3. Rest of Latin America

    12.3. Latin America HER2 Breast Cancer Test Market Value Share and Attractiveness analysis, by Test Type

    12.4. Latin America HER2 Breast Cancer Test Market Forecast, by Test Type

        12.4.1. Immunohistochemistry (IHC)

        12.4.2. Fluorescence/Chromogenic In Situ Hybridization (FISH/CISH)

    12.5. Latin America HER2 Breast Cancer Test Market Value Share and Attractiveness analysis, by End-user

    12.6. Latin America HER2 Breast Cancer Test Market Forecast, by End-user

        12.6.1. Hospitals

        12.6.2. Diagnostic Laboratories

13. Middle East & Africa HER2 Breast Cancer Test Market Analysis

    13.1. Middle East & Africa HER2 Breast Cancer Test Market Overview

    13.2. Middle East & Africa HER2 Breast Cancer Test Market Value Share and Attractiveness Analysis, by Country/Sub-region

        13.2.1. GCC Countries

        13.2.2. South Africa

        13.2.3. Rest of Middle East & Africa

    13.3. Middle East & Africa HER2 Breast Cancer Test Market Value Share and Attractiveness Analysis, by Test Type

    13.4. Middle East & Africa HER2 Breast Cancer Test Market Forecast, by Test Type

        13.4.1. Immunohistochemistry (IHC)

        13.4.2. Fluorescence/Chromogenic In Situ Hybridization (FISH/CISH)

    13.5. Middle East & Africa HER2 Breast Cancer Test Market Value Share and Attractiveness Analysis, by End-user

    13.6. Middle East & Africa HER2 Breast Cancer Test Market Forecast, by End-user

        13.6.1. Hospitals

14. Competition Landscape

    14.1. Market Player - Competition Matrix (by tier and size of companies)

    14.2. Market Share Analysis, by Company, 2019

    14.3. Company Profiles

        14.3.1. Abbott Laboratories

            14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.1.2. Product Portfolio

            14.3.1.3. SWOT Analysis

            14.3.1.4. Strategic Overview

        14.3.2. BioGenex

            14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.2.2. Product Portfolio

            14.3.2.3. SWOT Analysis

            14.3.2.4. Strategic Overview

        14.3.3. Agilent Technologies, Inc.

            14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.3.2. Product Portfolio

            14.3.3.3. SWOT Analysis

            14.3.3.4. Strategic Overview

        14.3.4. Leica Biosystems

            14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.4.2. Product Portfolio

            14.3.4.3. SWOT Analysis

            14.3.4.4. Strategic Overview

        14.3.5. Roche

            14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.5.2. Product Portfolio

            14.3.5.3. SWOT Analysis

            14.3.5.4. Strategic Overview

        14.3.6. Mylab Discovery Solutions Pvt. Ltd.

            14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.6.2. Product Portfolio

            14.3.6.3. SWOT Analysis

            14.3.6.4. Strategic Overview

List of Tables

Table 01: Global HER2 Breast Cancer Test Market Size (US$ Mn) Forecast, by Test Type, 2017–2031

Table 02: Global HER2 Breast Cancer Test Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 03: North America HER2 Breast Cancer Test Market Revenue (US$ Mn) Forecast, by Country, 2017–2031

Table 04: North America HER2 Breast Cancer Test Market Size (US$ Mn) Forecast, by Test Type, 2017–2031

Table 05: North America HER2 Breast Cancer Test Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 06: Europe HER2 Breast Cancer Test Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 07: Europe HER2 Breast Cancer Test Market Size (US$ Mn) Forecast, by Test Type, 2017–2031

Table 08: Europe HER2 Breast Cancer Test Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 09: Asia Pacific HER2 Breast Cancer Test Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 10: Asia Pacific HER2 Breast Cancer Test Market Size (US$ Mn) Forecast, by Test Type, 2017–2031

Table 11: Asia Pacific HER2 Breast Cancer Test Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 12: Latin America HER2 Breast Cancer Test Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 13: Latin America HER2 Breast Cancer Test Market Size (US$ Mn) Forecast, by Test Type, 2017–2031

Table 14: Latin America HER2 Breast Cancer Test Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 15: Middle East & Africa HER2 Breast Cancer Test Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 16: Middle East & Africa HER2 Breast Cancer Test Market Size (US$ Mn) Forecast, by Test Type, 2017–2031

Table 17: Middle East & Africa HER2 Breast Cancer Test Market Size (US$ Mn) Forecast, by End-user, 2017–2031

List of Figures

Figure 01: Global HER2 Breast Cancer Test Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Global HER2 Breast Cancer Test Market Value Share, by Test Type (2020)

Figure 03: Global HER2 Breast Cancer Test Market Value Share, by End-user (2020)

Figure 04: Global HER2 Breast Cancer Test Market Value Share, by Region (2020)

Figure 05: Global HER2 Breast Cancer Test Market Value Share Analysis, by Test Type, 2020 and 2031

Figure 06: Global HER2 Breast Cancer Test Market Revenue (US$ Mn), by Immunohistochemistry (IHC), 2017–2031

Figure 07: Global HER2 Breast Cancer Test Market Revenue (US$ Mn), by Fluorescence/Chromogenic In Situ Hybridization (FISH/CISH), 2017–2031

Figure 08: Global HER2 Breast Cancer Test Market Attractiveness Analysis, by Test Type, 2021–2031

Figure 09: Global HER2 Breast Cancer Test Market Value Share Analysis, by Region, 2020 and 2031

Figure 10: Global HER2 Breast Cancer Test Market Attractiveness, by Region, 2021-2031

Figure 11: North America HER2 Breast Cancer Test Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 12: North America HER2 Breast Cancer Test Market Value Share (%), by Country, 2020 and 2031

Figure 13: North America HER2 Breast Cancer Test Market Attractiveness, by Country, 2021–2031

Figure 14: North America HER2 Breast Cancer Test Market Value Share Analysis, by Test Type, 2020 and 2031

Figure 15: North America HER2 Breast Cancer Test Market Attractiveness, by Test Type, 2021–2031

Figure 16: North America HER2 Breast Cancer Test Market Value Share Analysis, by End-user, 2020 and 2031

Figure 17: North America HER2 Breast Cancer Test Market Attractiveness, by End-user, 2021–2031

Figure 18: Europe HER2 Breast Cancer Test Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 19: Europe HER2 Breast Cancer Test Market Value Share (%), by Country/Sub-region, 2020 and 2031

Figure 20: Europe HER2 Breast Cancer Test Market Attractiveness, by Country/Sub-region, 2021–2031

Figure 21: Europe HER2 Breast Cancer Test Market Value Share Analysis, by Test Type, 2020 and 2031

Figure 22 Europe HER2 Breast Cancer Test Market Attractiveness, by Test Type, 2021–2031

Figure 23: Europe HER2 Breast Cancer Test Market Value Share Analysis, by End-user, 2020 and 2031

Figure 24: Europe HER2 Breast Cancer Test Market Attractiveness, by End-user, 2021–2031

Figure 25: Asia Pacific HER2 Breast Cancer Test Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 26: Asia Pacific HER2 Breast Cancer Test Market Value Share (%), by Country/Sub-region, 2020 and 2031

Figure 27: Asia Pacific HER2 Breast Cancer Test Market Attractiveness, by Country/Sub-region, 2021–2031

Figure 28: Asia Pacific HER2 Breast Cancer Test Market Value Share Analysis, by Test Type, 2020 and 2031

Figure 29: Asia Pacific HER2 Breast Cancer Test Market Attractiveness, by Test Type, 2021–2031

Figure 30: Asia Pacific HER2 Breast Cancer Test Market Value Share Analysis, by End-user, 2020 and 2031

Figure 31: Asia Pacific HER2 Breast Cancer Test Market Attractiveness, by End-user, 2021–2031

Figure 32: Latin America HER2 Breast Cancer Test Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 33: Latin America HER2 Breast Cancer Test Market Value Share (%), by Country/Sub-region, 2020 and 2031

Figure 34: Latin America HER2 Breast Cancer Test Market Attractiveness, by Country/Sub-region, 2021–2031

Figure 35: Latin America HER2 Breast Cancer Test Market Value Share Analysis, by Test Type, 2020 and 2031

Figure 36: Latin America HER2 Breast Cancer Test Market Attractiveness, by Test Type, 2021–2031

Figure 37: Latin America HER2 Breast Cancer Test Market Value Share Analysis, by End-user, 2020 and 2031

Figure 38: Latin America HER2 Breast Cancer Test Market Attractiveness, by End-user, 2021–2031

Figure 39: Middle East & Africa HER2 Breast Cancer Test Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 40: Middle East & Africa HER2 Breast Cancer Test Market Value Share (%), by Country/Sub-region, 2020 and 2031

Figure 41: Middle East & Africa HER2 Breast Cancer Test Market Attractiveness, by Country/Sub-region, 2021–2031

Figure 42: Middle East & Africa HER2 Breast Cancer Test Market Value Share Analysis, by Test Type, 2020 and 2031

Figure 43: Middle East & Africa HER2 Breast Cancer Test Market Attractiveness, by Test Type, 2021–2031

Figure 44: Middle East & Africa HER2 Breast Cancer Test Market Value Share Analysis, by End-user, 2020 and 2031

Figure 45: Middle East & Africa HER2 Breast Cancer Test Market Attractiveness, by End-user, 2021–2031

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

306

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved